Track market-moving stories before they get noisy

The multiyear partnership is part of the food conglomerate's effort to reinvigorate its brands.

In a July 21 X post, the famous ‘Big Short’ trader, Michael Burry, drew attention to a study showing that big tech’s overall debt significantly exceeds the fully disclosed figures.

Specifically, the legendary investor highlighted a recent Nikkei Research study that found that just five U.S. technology giants carry as much as $1.65 trillion in so-called ‘hidden debt’ – burden that does not appear on the balance sheet thanks to a wide variety of obfuscating methods. 

The figure is made only more alarming once its growth is taken into account. Indeed, as recently as 2022, the number stood in the low hundreds of billions and has been steadily accelerating, with the 2026 balance anticipated to be roughly twice as high as in 2025.

PALO ALTO, California — Hidden debt at U.S. tech giants swelled eightfold in roughly four years to an estimated $1.65 trillion as artificial intelligence investments ballooned, a Nikkei study shows, exceeding actual debt and making it tougher for investors to assess risk.
Nikkei… pic.twitter.com/SW4eZ1rG1R

— Cassandra Unchained (@michaeljburry) July 21, 2026 Oracle debt soars 30x on OpenAI data center commitment Elsewhere, examining the Nikkei report more closely reveals that Meta’s (NASDAQ: META) off-balance-sheet debt is especially high at $420 billion, while Oracle’s (NYSE: ORCL) has been rising at a particularly rapid rate.

According to the study, Oracle saw its burden soar roughly 30-fold over four years, reaching $273.3 billion by the end of May. 

Notably, the firm might be particularly exposed to any adverse developments in the wider AI space, considering its ability to pay back the debt is mostly reliant on the future profitability and success of OpenAI.

Simultaneously, leaked financials for 2024 and 2025 for Sam Altman’s firm strongly hint that the company might not be able to pay Oracle in time, if at all.

Meanwhile, recent developments showcase both the continued confidence blue-chip technology giants have in the eventual benefits of their vast infrastructure investments and the strain the greater program has put on credit providers.

Alphabet (NASDAQ: GOOGL) – one of the firms included in the $1.65 trillion total – recently made its first equity offering in roughly two decades, raising over $80 billion from Warren Buffett and other investors across the market.

Possible signs of strain are also evident with the last two examined companies – Microsoft (NASDAQ: MSFT) and Amazon (NASDAQ: AMZN) – as both have been undertaking significant layoffs in what some critics speculate are attempts to save cash to facilitate continued CapEx.

As for Michael Burry, the $1.65 trillion in hidden debt for some of the biggest technology firms involved with the ‘AI boom’ appears to back his long-standing thesis that the prevailing situation in the market is unsustainable.

The legendary short trader drew much scrutiny in recent years with his attempts to bet against the semiconductor industry, and his more recent wagers that Nvidia (NASDAQ: NVDA) and Palantir (NASDAQ: PLTR) stocks would experience a decline have, so far, been offering mixed results.

Lastly, the situation might shift once again already in July as nearly all companies included in the study are set to report their quarterly earnings, with the probable continuation of the trend possibly proving especially damaging given that big tech owes much of its popularity to historically being asset-light and cash-heavy.

Featured image via Shutterstock

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

Posted by Defense World Staff on Jul 21st, 2026

AlTi Global Inc. reduced its position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 92.0% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 9,221 shares of the biopharmaceutical company’s stock after selling 105,548 shares during the period. AlTi Global Inc.’s holdings in Bristol Myers Squibb were worth $559,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares during the last quarter. State Street Corp increased its stake in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after acquiring an additional 1,385,206 shares during the last quarter. Geode Capital Management LLC raised its stake in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $1,947,272,000. Finally, AQR Capital Management LLC raised its position in shares of Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after buying an additional 16,332,924 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth BMY has been the subject of a number of research reports. Weiss Ratings downgraded Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Bank of America decreased their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Finally, Guggenheim restated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.25.

Get Our Latest Stock Analysis on Bristol Myers Squibb

Bristol Myers Squibb Trading Down 0.7% NYSE:BMY opened at $60.30 on Tuesday. The business’s 50-day moving average is $57.11 and its two-hundred day moving average is $57.85. The firm has a market capitalization of $123.14 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Key Stories Impacting Bristol Myers Squibb Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon About Bristol Myers Squibb (Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Featured Articles Five stocks we like better than Bristol Myers Squibb The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEASML Holding N.V. $ASML Shares Sold by AlTi Global Inc.

NEXT HEADLINE »Amova Asset Management Americas Inc. Sells 54,907 Shares of Nu Holdings Ltd. $NU

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lessened its stake in Roku, Inc. (NASDAQ:ROKU – Free Report) by 37.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,848,889 shares of the company’s stock after selling 1,092,615 shares during the quarter. Roku comprises 2.5% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 11th biggest position. Amova Asset Management Americas Inc. owned 1.25% of Roku worth $174,923,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Jefferies Financial Group Inc. acquired a new position in shares of Roku during the 4th quarter valued at $1,345,000. Moran Wealth Management LLC acquired a new stake in Roku in the first quarter worth $2,990,000. MH & Associates Securities Management Corp ADV bought a new stake in Roku in the fourth quarter valued at $2,398,000. Katamaran Capital LLP increased its stake in Roku by 90.8% in the first quarter. Katamaran Capital LLP now owns 52,548 shares of the company’s stock valued at $4,972,000 after purchasing an additional 25,002 shares in the last quarter. Finally, Maxi Investments CY Ltd acquired a new position in shares of Roku during the fourth quarter valued at about $1,953,000. Institutional investors own 86.30% of the company’s stock.

Roku Stock Down 0.2% Shares of NASDAQ:ROKU opened at $144.13 on Tuesday. The stock has a market cap of $21.25 billion, a price-to-earnings ratio of 108.37 and a beta of 2.01. Roku, Inc. has a 12-month low of $78.53 and a 12-month high of $148.88. The business’s 50 day moving average is $133.04 and its 200 day moving average is $112.78.

Roku (NASDAQ:ROKU – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.23. The business had revenue of $1.25 billion during the quarter, compared to the consensus estimate of $1.20 billion. Roku had a return on equity of 7.64% and a net margin of 4.06%.Roku’s revenue was up 22.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.19) earnings per share. As a group, equities research analysts expect that Roku, Inc. will post 2.41 earnings per share for the current year.

Analyst Upgrades and Downgrades A number of research firms have recently issued reports on ROKU. Citigroup increased their price objective on shares of Roku from $120.00 to $157.00 and gave the stock a “neutral” rating in a research report on Friday. Susquehanna downgraded Roku from a “positive” rating to a “neutral” rating and set a $160.00 price target on the stock. in a research note on Tuesday, June 16th. Zacks Research lowered Roku from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 14th. Morgan Stanley raised their price objective on Roku from $150.00 to $170.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Finally, UBS Group set a $160.00 price objective on Roku in a report on Monday, June 15th. Ten research analysts have rated the stock with a Buy rating and seventeen have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $155.12.

Get Our Latest Stock Analysis on ROKU

Insider Activity at Roku In related news, insider Charles Collier sold 20,538 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $124.23, for a total transaction of $2,551,435.74. Following the transaction, the insider directly owned 7,700 shares in the company, valued at approximately $956,571. The trade was a 72.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gilbert Fuchsberg sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $125.52, for a total value of $1,204,113.36. Following the completion of the transaction, the insider owned 50,863 shares in the company, valued at $6,384,323.76. The trade was a 15.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 236,499 shares of company stock valued at $30,582,963 over the last three months. Insiders own 13.45% of the company’s stock.

Roku Profile (Free Report)

Roku, Inc (NASDAQ: ROKU) is a technology company that develops and operates a proprietary streaming platform designed to deliver entertainment content to consumers via internet-connected devices and smart televisions. Since its inception in 2002 in California, Roku has focused on simplifying access to streaming services for viewers worldwide. The company’s platform enables users to discover, access and manage a wide array of over-the-top content from major streaming services, free ad-supported channels and niche providers.

At the core of Roku’s product lineup are a range of streaming players and sticks, which connect to televisions via HDMI and deliver the Roku OS experience.

Further Reading Five stocks we like better than Roku The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ROKU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roku, Inc. (NASDAQ:ROKU – Free Report).

Receive News & Ratings for Roku Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roku and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINERoyalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc.

NEXT HEADLINE »Block, Inc. $XYZ Shares Sold by Amova Asset Management Americas Inc.

Micron Technology (NASDAQ: MU) could face modest downside over the coming days, according to the latest forecast generated by the Finbold AI Agent. 

The machine learning model projects Micron stock to trade at an average price of $849.66 on August 1, 2026, representing a 1.92% decline from its reference price of $866.30.

MU stock price prediction. Source: Finbold The forecast comes after a period of heightened volatility for Micron shares, which have surged on the back of booming artificial intelligence demand and strong pricing across the memory semiconductor market. 

While Wall Street remains broadly bullish on the company’s long-term outlook, the AI-powered prediction suggests MU stock could experience short-term pressure before the start of August.

The Finbold AI Agent aggregates forecasts from multiple large language models and machine learning systems to estimate future price movements. For Micron, the models produced a range of outcomes for August 1.

GPT-5.6 Sol delivered the most optimistic forecast, projecting MU shares at $910, implying a 5.04% gain. Gemini 3.5 Flash predicted a price of $855, while Claude Opus 4.8 forecast $815.20. Grok 4.5 was also cautious, estimating a price target of $818.45.

Combining the individual forecasts resulted in an average projected price of $849.66, suggesting a modest pullback from current levels.

MU stock price prediction. Source: Finbold MU stock fundamentals Despite the near-term bearish forecast, Micron continues to benefit from strong demand for high-bandwidth memory (HBM) and other AI-related memory products.

The company reported record fiscal third-quarter 2026 revenue of $41.46 billion, significantly exceeding analyst expectations. 

Non-GAAP earnings per share reached $25.11, while management issued fourth-quarter revenue guidance of approximately $50 billion, reflecting continued momentum in AI infrastructure spending.

Micron has also stated that its HBM supply for 2026 is fully sold out, with demand visibility extending into 2027. These trends have helped drive one of the strongest stock performances in the semiconductor sector this year.

Micron stock technical indicators  The Finbold AI Agent’s forecast aligns with recent technical weakness in Micron shares. The stock has retreated sharply from its all-time highs, while momentum indicators have softened.

The Relative Strength Index (RSI) has trended lower in recent weeks, indicating fading buying pressure. At the same time, the Moving Average Convergence Divergence (MACD) indicator remains under pressure, reflecting a slowdown in upward momentum following the stock’s rapid advance earlier in the year.

While Micron’s long-term outlook remains supported by AI-driven memory demand, the machine learning forecast suggests investors could see additional short-term volatility before August begins.

Best Crypto Exchange for Intermediate Traders and Investors

Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

Copy top-performing traders in real time, automatically.

eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide

eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong. Take 2 mins to learn more.

Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!

Posted by Defense World Staff on Jul 21st, 2026

AlTi Global Inc. grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) by 353.2% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,023 shares of the medical equipment provider’s stock after purchasing an additional 2,356 shares during the quarter. AlTi Global Inc.’s holdings in Intuitive Surgical were worth $1,394,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Fiduciary Financial Group LLC boosted its position in shares of Intuitive Surgical by 2.1% in the fourth quarter. Fiduciary Financial Group LLC now owns 920 shares of the medical equipment provider’s stock worth $521,000 after purchasing an additional 19 shares during the period. Prosperity Consulting Group LLC raised its position in shares of Intuitive Surgical by 0.5% during the 3rd quarter. Prosperity Consulting Group LLC now owns 4,033 shares of the medical equipment provider’s stock valued at $1,804,000 after purchasing an additional 19 shares during the period. Sunburst Financial Group LLC lifted its stake in shares of Intuitive Surgical by 4.3% during the 4th quarter. Sunburst Financial Group LLC now owns 485 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 20 shares in the last quarter. WoodTrust Financial Corp boosted its holdings in Intuitive Surgical by 0.5% in the 4th quarter. WoodTrust Financial Corp now owns 4,180 shares of the medical equipment provider’s stock worth $2,367,000 after buying an additional 20 shares during the period. Finally, North Star Investment Management Corp. boosted its holdings in Intuitive Surgical by 8.5% in the 4th quarter. North Star Investment Management Corp. now owns 269 shares of the medical equipment provider’s stock worth $152,000 after buying an additional 21 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In A number of research firms have commented on ISRG. Raymond James Financial reissued an “outperform” rating and set a $483.00 price target (down from $577.00) on shares of Intuitive Surgical in a report on Friday. BMO Capital Markets reissued an “outperform” rating on shares of Intuitive Surgical in a research note on Monday. Robert W. Baird lowered their price target on Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating on the stock in a report on Friday. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a research note on Tuesday, May 19th. Finally, Evercore set a $430.00 price objective on shares of Intuitive Surgical in a report on Monday, July 6th. Twenty-one analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $523.46.

Read Our Latest Research Report on Intuitive Surgical

Intuitive Surgical Stock Performance NASDAQ:ISRG opened at $353.17 on Tuesday. The firm has a market capitalization of $125.08 billion, a PE ratio of 40.45, a PEG ratio of 2.80 and a beta of 1.46. The stock’s fifty day moving average is $413.94 and its 200 day moving average is $465.58. Intuitive Surgical, Inc. has a fifty-two week low of $342.10 and a fifty-two week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its quarterly earnings data on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, topping the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a net margin of 28.45% and a return on equity of 17.09%. The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.62 billion. During the same period in the previous year, the firm earned $1.81 earnings per share. Intuitive Surgical’s quarterly revenue was up 23.0% compared to the same quarter last year. Equities analysts forecast that Intuitive Surgical, Inc. will post 8.62 EPS for the current year.

Insider Activity at Intuitive Surgical In related news, SVP Iman Jeddi sold 5,625 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $420.55, for a total value of $2,365,593.75. Following the sale, the senior vice president directly owned 6,463 shares of the company’s stock, valued at $2,718,014.65. This represents a 46.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $424.14, for a total value of $169,656.00. Following the completion of the sale, the executive vice president owned 5,720 shares in the company, valued at approximately $2,426,080.80. The trade was a 6.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 7,169 shares of company stock worth $3,059,135. Insiders own 0.60% of the company’s stock.

Key Intuitive Surgical News Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: Some market commentary argues ISRG’s recent correction may have reset expectations, with oversold technical conditions and improving earnings estimate revisions potentially setting up a near-term rebound. Down 15% in 4 Weeks, Here’s Why You Should You Buy the Dip in Intuitive Surgical (ISRG) Positive Sentiment: Zacks highlighted Intuitive Surgical as a trending stock with strong growth characteristics, saying the company’s fundamentals and growth profile may appeal to investors looking for long-term outperformance. 3 Reasons Growth Investors Will Love Intuitive Surgical (ISRG) Positive Sentiment: Another piece noted investor interest in ISRG remains elevated, suggesting the stock is staying on traders’ radar even after recent weakness. Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It Neutral Sentiment: Commentary focused on whether investors should prioritize Intuitive Surgical’s current robot sales or its longer-term growth opportunity, reinforcing the debate around valuation versus future expansion. What’s More Important For Intuitive Surgical: Today’s Robots Or Tomorrow’s Growth? Negative Sentiment: Several analyst updates were cautious, with firms including Stifel, Sanford C. Bernstein, and Citigroup lowering price targets or expectations, which likely added to the selling pressure on ISRG. Stifel Nicolaus Lowers Intuitive Surgical (NASDAQ:ISRG) Price Target to $550.00 About Intuitive Surgical (Free Report)

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.

See Also Five stocks we like better than Intuitive Surgical The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlTi Global Inc. Purchases New Holdings in Grayscale Bitcoin Mini Trust ETF $BTC

NEXT HEADLINE »Amova Asset Management Americas Inc. Sells 4,933 Shares of MercadoLibre, Inc. $MELI

A securities fraud class action lawsuit has been filed on behalf of Zillow investors after its stock plummeted over 16% because of Zillow's alleged anticompetitive agreement with Redfin, potentially violating federal securities laws.

, /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Zillow Group, Inc. (NASDAQ:Z, ZG) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.

If you invested in Zillow, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/zillow-class-action-lawsuit.

Key Details of the Zillow ($Z, $ZG) Class Action:

Lead Plaintiff Deadline: August 10, 2026 Alleged Misconduct: Securities fraud relating to Zillow's allegedly anticompetitive agreement with Redfin Corporation Largest Alleged Stock Drop: February 11, 2026 – 16.54% Stock Drop on Class C shares; 17.13% Stock Drop on Class A shares. Court: U.S. District Court for the Western District of Washington Action: Contact BFA Law to discuss your rights Investors have until August 10, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Zillow Class C and Class A common stock. The class action is pending in the U.S. District Court for the Western District of Washington. It is captioned Breidert v. Zillow Group, Inc., et al., No. 26-cv-02016.

Why is Zillow Being Sued for Securities Fraud?

On February 6, 2025, Zillow entered into an agreement with Redfin through which Zillow became the exclusive provider of multifamily rental listings on Redfin's platform and affiliate websites, including Rent.com. According to the complaint, during the relevant period, Zillow characterized the agreement with Redfin as a "partnership" that would provide Zillow exclusive access to Redfin's advertising platform.

As alleged, in truth, under the terms of the agreement, Zillow paid Redfin $100 million to stop competing with Zillow, facilitate the transition of its multifamily rental advertising business to Zillow, and close the remainder of its business. 

Why did Zillow's Stock Drop?

On September 30, 2025, the FTC filed a complaint against Zillow and Redfin alleging violations of the federal antitrust laws. According to the FTC complaint, "Zillow and Redfin executed an unlawful agreement to remove competition from [the online rental marketplaces industry], starting with a $100 million payment to Redfin to exit the [Internet Listing Services] market." In sum, the FTC alleged, "[t]his agreement is nothing more than an end run around competition on the merits with Redfin for customers…" This news caused the price of Zillow's Class C and A common stock to decline 4.33% and 4.5%, respectively.

On February 10, 2026, Zillow's CFO told investors that Zillow experienced increased legal expenses which "will result in approximately 200 basis points headwind to EBITDA margins in Q1." On this news, the price of Zillow's Class C and A common stock declined 16.54%, and 17.13%, respectively.

Finally, on May 7, 2026, Reuters reported that a "federal judge rejected [Zillow and Redfin's] request to end a [FTC] lawsuit accusing them of illegally agreeing to suppress competition for online apartment rental listings." This news caused the price of Zillow's Class C and A common stock to decline 1.9% and 1.76%, respectively.

Click here for more information: https://www.bfalaw.com/cases/zillow-class-action-lawsuit.

What Can You Do?

If you invested in Zillow, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/zillow-class-action-lawsuit

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients."

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/zillow-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

SOURCE Bleichmar Fonti & Auld LLP

Posted by Defense World Staff on Jul 21st, 2026

AlTi Global Inc. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 312.7% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,857 shares of the biopharmaceutical company’s stock after purchasing an additional 1,407 shares during the period. AlTi Global Inc.’s holdings in Regeneron Pharmaceuticals were worth $1,435,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Nordea Investment Management AB increased its position in shares of Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after acquiring an additional 74,350 shares in the last quarter. Lockheed Martin Investment Management Co. purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $2,702,000. Asio Capital LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $3,422,000. Robeco Institutional Asset Management B.V. boosted its stake in Regeneron Pharmaceuticals by 116.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock worth $202,114,000 after purchasing an additional 140,966 shares during the period. Finally, National Pension Service grew its position in Regeneron Pharmaceuticals by 29.8% during the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock worth $278,636,000 after purchasing an additional 82,853 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals In related news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.7% Shares of NASDAQ:REGN opened at $672.15 on Tuesday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $71.06 billion, a PE ratio of 16.38, a P/E/G ratio of 1.50 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11. The firm has a fifty day moving average price of $640.18 and a 200 day moving average price of $717.26.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business’s revenue was up 19.0% compared to the same quarter last year. During the same period last year, the company earned $8.22 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Wall Street Analyst Weigh In A number of analysts have recently issued reports on REGN shares. HSBC reduced their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Royal Bank Of Canada decreased their price objective on Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Canaccord Genuity Group lowered their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Finally, Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research report on Wednesday, April 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $787.67.

View Our Latest Analysis on Regeneron Pharmaceuticals

Key Stories Impacting Regeneron Pharmaceuticals Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Negative Sentiment: Multiple law firms, including Bernstein Liebhard, Levi & Korsinsky, the Schall Law Firm, the DJS Law Group, Faruqi & Faruqi, and Bronstein, Gewirtz & Grossman, announced or reminded investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN), with a lead plaintiff deadline of September 14, 2026. These notices suggest potential litigation risk and uncertainty for shareholders. Article Title Negative Sentiment: The lawsuit coverage increases headline risk and could weigh on sentiment until more details emerge about the alleged claims and the company’s response. Article Title Neutral Sentiment: The company previously reported strong quarterly results, including earnings and revenue that beat expectations, which remains a supportive backdrop for the stock even as legal issues dominate near-term trading. MarketBeat Regeneron Pharmaceuticals Profile (Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

See Also Five stocks we like better than Regeneron Pharmaceuticals The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAlTi Global Inc. Makes New Investment in Establishment Labs Holdings Inc. $ESTA

NEXT HEADLINE »AlTi Global Inc. Has $1.14 Million Holdings in Paramount Skydance Corporation $PSKY

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. lowered its position in shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM – Free Report) by 12.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 312,975 shares of the semiconductor company’s stock after selling 44,653 shares during the quarter. Taiwan Semiconductor Manufacturing makes up about 1.5% of Amova Asset Management Americas Inc.’s investment portfolio, making the stock its 19th largest position. Amova Asset Management Americas Inc.’s holdings in Taiwan Semiconductor Manufacturing were worth $105,782,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TSM. Quattro Advisors LLC bought a new stake in shares of Taiwan Semiconductor Manufacturing during the fourth quarter worth approximately $25,000. Hilton Head Capital Partners LLC bought a new position in Taiwan Semiconductor Manufacturing in the fourth quarter valued at approximately $27,000. Stephens Consulting LLC grew its holdings in Taiwan Semiconductor Manufacturing by 82.0% during the 4th quarter. Stephens Consulting LLC now owns 91 shares of the semiconductor company’s stock worth $28,000 after acquiring an additional 41 shares during the period. Strategic Advocates LLC grew its holdings in Taiwan Semiconductor Manufacturing by 62.1% during the 4th quarter. Strategic Advocates LLC now owns 94 shares of the semiconductor company’s stock worth $28,000 after acquiring an additional 36 shares during the period. Finally, Ares Financial Consulting LLC bought a new stake in shares of Taiwan Semiconductor Manufacturing during the 4th quarter valued at $29,000. Institutional investors and hedge funds own 16.51% of the company’s stock.

More Taiwan Semiconductor Manufacturing News Here are the key news stories impacting Taiwan Semiconductor Manufacturing this week:

Positive Sentiment: TSMC reported record second-quarter results, with revenue growth, strong margins, and raised full-year guidance, reinforcing that AI chip demand remains robust. Positive Sentiment: Several bullish commentaries and analyst notes argue the post-earnings pullback may be a buying opportunity, citing sustained AI-driven growth and expanding leading-edge production. Positive Sentiment: The company said demand for AI chips should stay strong for years, and its expanded Arizona investment underscores confidence in long-term capacity needs and customer demand. Reuters article on AI demand and Arizona investment Positive Sentiment: Coverage citing billionaire investors and “AI capex winners” has kept TSMC in the spotlight as one of the clearest beneficiaries of the AI buildout. Neutral Sentiment: Some articles frame the move as a valuation and positioning reset after a strong run, suggesting part of the recent weakness may reflect profits being taken rather than a change in fundamentals. Seeking Alpha article on what was priced in Negative Sentiment: Investors are worried the extra $100 billion Arizona plan could pressure near-term profit margins, especially with construction labor and infrastructure constraints. Negative Sentiment: Broader semiconductor weakness and bear-market concerns in the sector are also weighing on sentiment, even though TSMC’s own results remain strong. Insider Buying and Selling at Taiwan Semiconductor Manufacturing In related news, VP Bor-Zen Tien purchased 2,000 shares of the business’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average price of $69.91 per share, with a total value of $139,820.00. Following the completion of the purchase, the vice president owned 11,051 shares in the company, valued at $772,575.41. This represents a 22.10% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Tzu-Sou Chuang sold 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $69.83, for a total transaction of $13,966,000.00. Following the completion of the transaction, the vice president owned 2,495,165 shares of the company’s stock, valued at $174,237,371.95. This trade represents a 7.42% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have purchased 6,857 shares of company stock valued at $512,334. 1.11% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes A number of research firms have recently weighed in on TSM. Barclays increased their price target on Taiwan Semiconductor Manufacturing from $625.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday. TD Cowen increased their target price on Taiwan Semiconductor Manufacturing from $400.00 to $440.00 and gave the company a “hold” rating in a research note on Friday. Needham & Company LLC raised their target price on Taiwan Semiconductor Manufacturing from $410.00 to $480.00 and gave the stock a “buy” rating in a report on Thursday, April 16th. Citigroup restated a “buy” rating on shares of Taiwan Semiconductor Manufacturing in a research report on Monday, July 6th. Finally, Susquehanna increased their price target on shares of Taiwan Semiconductor Manufacturing from $575.00 to $600.00 and gave the company a “positive” rating in a research report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $490.00.

Get Our Latest Report on Taiwan Semiconductor Manufacturing

Taiwan Semiconductor Manufacturing Stock Up 1.0% NYSE:TSM opened at $402.49 on Tuesday. Taiwan Semiconductor Manufacturing Company Ltd. has a 1 year low of $223.70 and a 1 year high of $479.00. The stock has a 50-day moving average price of $426.76 and a two-hundred day moving average price of $379.20. The stock has a market cap of $2.09 trillion, a price-to-earnings ratio of 29.04, a PEG ratio of 0.95 and a beta of 1.36. The company has a current ratio of 2.49, a quick ratio of 2.31 and a debt-to-equity ratio of 0.16.

Taiwan Semiconductor Manufacturing (NYSE:TSM – Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The semiconductor company reported $4.28 EPS for the quarter. Taiwan Semiconductor Manufacturing had a return on equity of 40.88% and a net margin of 50.31%.The company had revenue of $39.89 billion for the quarter. As a group, equities analysts expect that Taiwan Semiconductor Manufacturing Company Ltd. will post 15.83 earnings per share for the current year.

Taiwan Semiconductor Manufacturing Increases Dividend The business also recently announced a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Wednesday, September 16th will be issued a dividend of $1.1136 per share. This is an increase from Taiwan Semiconductor Manufacturing’s previous quarterly dividend of $0.95. The ex-dividend date is Wednesday, September 16th. This represents a $4.45 annualized dividend and a yield of 1.1%. Taiwan Semiconductor Manufacturing’s dividend payout ratio is 21.43%.

About Taiwan Semiconductor Manufacturing (Free Report)

Taiwan Semiconductor Manufacturing Company (TSMC) is a leading pure-play semiconductor foundry that provides wafer fabrication and related services to the global semiconductor industry. Founded in 1987 by Morris Chang and headquartered in Hsinchu, Taiwan, TSMC manufactures integrated circuits on behalf of fabless and integrated device manufacturers, offering contract chip production across a broad set of technologies and products.

TSMC’s service offering covers logic and mixed-signal process technologies, specialty processes for radio-frequency, power management and embedded memory, and advanced nodes used in mobile, high-performance computing and AI applications.

Recommended Stories Five stocks we like better than Taiwan Semiconductor Manufacturing The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding TSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM – Free Report).

Receive News & Ratings for Taiwan Semiconductor Manufacturing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taiwan Semiconductor Manufacturing and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Increases Stake in Toast, Inc. $TOST

NEXT HEADLINE »AlTi Global Inc. Acquires New Position in Golub Capital BDC, Inc. $GBDC

AlTi Global Inc. lowered its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 54.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,563 shares of the healthcare product maker’s stock after selling 12,779 shares during the period. AlTi Global Inc.’s holdings in Abbott Laboratories were worth $1,085,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after buying an additional 2,402,408 shares in the last quarter. State Street Corp lifted its stake in Abbott Laboratories by 2.1% in the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock worth $10,004,880,000 after purchasing an additional 1,627,791 shares in the last quarter. Capital International Investors boosted its holdings in shares of Abbott Laboratories by 2.6% during the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP grew its position in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares in the last quarter. Finally, Capital Research Global Investors increased its holdings in shares of Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock valued at $4,907,523,000 after purchasing an additional 400,400 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes A number of equities analysts have weighed in on the company. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research note on Wednesday, April 22nd. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price target on the stock. Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, July 7th. Citigroup upped their price objective on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a report on Friday. Finally, Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $118.61.

Read Our Latest Report on Abbott Laboratories

Insiders Place Their Bets In other news, Director Daniel J. Starks bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Up 1.0% Shares of ABT opened at $101.72 on Tuesday. The company’s 50-day moving average price is $90.28 and its 200 day moving average price is $101.84. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a market cap of $177.18 billion, a P/E ratio of 32.92, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Articles Five stocks we like better than Abbott Laboratories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

, /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

Key Second Quarter 2026 Results

Net earnings were $870 million, or $1.23 per diluted common share, up 60% year-over-year. Non-GAAP adjusted diluted net earnings per common share grew 8.0% to $1.94. Revenues increased 5.5% year-over-year to $6.3 billion. Non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue excluding respiratory testing revenue increased 4.5% year-over-year. Operating cash flow was $1.5 billion and non-GAAP free cash flow was $1.3 billion. Strong Q2 earnings performance and earlier-than-anticipated completion of Masimo acquisition enabling increased full year 2026 adjusted diluted net earnings per common share guidance. Rainer M. Blair, President and Chief Executive Officer, stated, "We delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth. Our Life Sciences businesses delivered their strongest quarter in several years and while customer project timing impacted bioprocessing revenue, underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter."

Mr. Blair continued, "Looking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate. Longer term, Danaher's leading portfolio, capital deployment optionality and talented team — all powered by the Danaher Business System — position us to accelerate the impact of science and technology, help customers move from discovery to delivery faster, and create sustainable long-term shareholder value."

Third Quarter and Full Year 2026 Outlook

Danaher Corporation (the "Company") does not reconcile non-GAAP forecasted core sales growth, adjusted operating profit margin and adjusted diluted net earnings per common share to their respective, comparable measure prepared in accordance with U.S. generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $0.5 billion for the third quarter and $1.9 billion for the year ending December 31, 2026 and the estimated impact of foreign currency on sales, which is estimated to decrease sales by 1.0% in the third quarter and increase sales by 0.5% in the full year, assuming the currency exchange rates in effect as of June 26, 2026) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, future acquisitions, divested product lines, discrete tax adjustments, impairments, gains and losses on investments and the outcome of legal proceedings) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control. The impact of these additional elements could be material to our results computed in accordance with GAAP.

For the third quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the 2.0% to 3.0% range year-over-year.

For full year 2026, the Company expects non-GAAP core revenue will increase in the 3.0% to 4.0% range year-over-year. The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.45 to $8.60 versus previous guidance of $8.35 to $8.55.

Conference Call and Webcast Information

Danaher will discuss its second quarter results and financial guidance for the third quarter and full year 2026, including as applicable key assumptions with respect thereto, during its investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

The conference call can be accessed by dialing 833-419-0865, within the U.S. or +1 785-838-9333 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (Conference ID: DHRQ226). A replay of the conference call will be available shortly after the conclusion of the call and until August 4, 2026. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."

ABOUT DANAHER

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

NON-GAAP MEASURES AND SUPPLEMENTAL MATERIALS

In addition to the financial measures prepared in accordance with GAAP, this earnings release also contains non-GAAP financial measures. Calculations of these measures, explanations of what these measures represent and the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, where applicable, and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.

In addition, this earnings release, the slide presentation accompanying the related earnings call, non-GAAP reconciliations and a note containing details of historical and anticipated, future financial performance have been posted to the "Investors" section of Danaher's website (www.danaher.com).

FORWARD-LOOKING STATEMENTS AND OTHER INFORMATION

Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial results for the third quarter and full year 2026, the Company's expectations regarding growth and market recovery, the Company's positioning to create long-term shareholder value, and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of our debt obligations (including debt we incurred to finance the acquisition of Masimo Corporation) on our operations and liquidity, deterioration of or instability in the global economy, the markets we serve and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to our acquisition of Masimo Corporation), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, security breaches or other disruptions of our information technology systems or violations of data privacy laws, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation, regulatory proceedings and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to our manufacturing operations, the impact of climate change, legal or regulatory measures to address climate change and other sustainability topics and our ability to address regulatory requirements or stakeholder expectations relating to climate change and other sustainability topics, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, labor matters and our ability to recruit, retain and motivate talented employees, U.S. and non-U.S. economic, political, geopolitical, legal, compliance, social and business factors (including the impact of elections, regulatory and policy changes or uncertainty, government shutdowns and military conflicts such as the conflict in the Middle East), disruptions and other impacts relating to man-made and natural disasters, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2026. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

This press release may include descriptions of certain products and/or devices that have applications submitted and pending for certain regulatory approvals, or are available only in certain markets.

DANAHER CORPORATION AND SUBSIDIARIES

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS

($ and shares in millions, except per share amounts)

(unaudited)

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Sales

$           6,265

$           5,936

$          12,216

$          11,677

Cost of sales

(2,654)

(2,413)

(5,014)

(4,643)

Gross profit

3,611

3,523

7,202

7,034

Operating costs:

Selling, general and administrative expenses     

(2,072)

(2,360)

(3,932)

(4,218)

Research and development expenses

(412)

(403)

(799)

(782)

Operating profit

1,127

760

2,471

2,034

Nonoperating income (expense):

Other income (expense), net

(3)

(42)

(76)

(121)

Interest expense

(107)

(71)

(170)

(143)

Interest income

61

8

88

14

Earnings before income taxes

1,078

655

2,313

1,784

Income taxes

(208)

(100)

(414)

(275)

Net earnings

$              870

$              555

$           1,899

$           1,509

Net earnings per common share:

Basic

$             1.23

$             0.77

$             2.69

(a)

$             2.11

(a)

Diluted

$             1.23

$             0.77

$             2.68

$             2.10

(a)

Average common stock and common
equivalent shares outstanding:

Basic

705.3

716.5

706.6

716.4

Diluted

707.6

719.1

709.4

719.9

(a) Net earnings per common share amounts for the relevant three-month periods do not add to the six-month period amount due to rounding.

This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com).

Diluted Net Earnings Per Common Share and Adjusted Diluted Net Earnings Per Common Share 

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Diluted Net Earnings Per Common Share     
(GAAP)

$             1.23

$             0.77

$             2.68

$             2.10

Amortization of acquisition-related
intangible assets A

0.65

0.59

1.26

1.16

Fair value net (gains) losses on
investments B

0.01

0.06

0.12

0.19

Acquisition-related items C

0.15

—

0.18

—

Impairments D

—

0.60

—

0.62

Gain on a product line disposition E

—

—

—

(0.01)

Tax effect of the above adjustments F

(0.13)

(0.26)

(0.27)

(0.39)

Discrete tax adjustments G

0.03

0.03

0.03

0.02

Rounding

—

0.01

—

(0.01)

Adjusted Diluted Net Earnings Per
Common Share (Non-GAAP)

$             1.94

$             1.80

$             4.00

$             3.68

Notes to Reconciliation of GAAP to Non-GAAP Financial Measures

A

Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above):

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Pretax

$              463

$              426

$              897

$              836

After-tax     

384

354

744

694

B 

Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the fair value net (gains) losses on investments line above):

Three-Month Period Ended

Six-Month Period Ended

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Pretax

$                 7

$               44

$               84

$              134

After-tax     

5

33

64

101

C 

Fair value adjustments to inventory, transaction costs deemed significant and pre-acquisition share-based and change-in-control payments, in each case related to the acquisition of Masimo Corporation ("Masimo") in the three and six-month periods ended June 26, 2026 ($108 million and $125 million pretax as reported in this line item, $95 million and $110 million after-tax). The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.

D 

Impairment charges related to a trade name in the Life Sciences segment recorded in the three and six-month periods ended June 27, 2025 ($432 million pretax as reported in this line item, $328 million after-tax) and a facility in the Biotechnology segment recorded in the six-month period ended June 27, 2025 ($15 million pretax as reported in this line item, $11 million after-tax).

E 

Gain on a product line disposition in the six-month period ended June 27, 2025 ($9 million pretax as reported in this line item, $7 million after-tax).

F 

This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment.

G 

Discrete tax adjustments and other tax-related adjustments for both the three and six-month periods ended June 26, 2026, include the impact of net discrete tax charges of $21 million related primarily to changes in estimates associated with prior period uncertain tax positions, partially offset by benefits from the release of reserves for uncertain tax positions resulting from audit settlements and the expiration of statutes of limitations during the six-month period. Discrete tax adjustments and other tax-related adjustments for the three-month period ended June 27, 2025, include the impact of net discrete tax charges of $22 million related primarily to changes in uncertain tax positions and other items. Discrete tax adjustments and other tax-related adjustments for the six-month period ended June 27, 2025, include the impact of net discrete tax charges of $12 million related primarily to the release of reserves for uncertain tax positions due to the expiration of statutes of limitations, partially offset by changes in uncertain tax positions and other items.

Sales Growth by Segment, Core Sales Growth (Decline) by Segment and Core Sales Growth Excluding Respiratory Testing

% Change Three-Month Period Ended June 26, 2026 vs. Comparable 2025 Period

Segments

Total Company

Biotechnology

Life Sciences

Diagnostics

Total sales growth (GAAP)

5.5 %

4.0 %

5.5 %

7.0 %

Impact of:

Acquisitions

(1.5) %

— %

— %

(4.0) %

Currency exchange rates

(1.0) %

(1.5) %

— %

(1.0) %

Core sales growth (non-GAAP)

3.0 %

2.5 %

5.5 %

2.0 %

Impact of respiratory testing

1.5 %

3.0 %

Core sales growth excluding respiratory
testing (non-GAAP)     

4.5 %

5.0 %

% Change Six-Month Period Ended June 26, 2026 vs. Comparable 2025 Period

Segments

Total Company

Biotechnology

Life Sciences

Diagnostics

Total sales growth (GAAP)

4.5 %

7.5 %

4.5 %

2.5 %

Impact of:

Acquisitions

(0.5) %

— %

— %

(2.0) %

Currency exchange rates

(2.0) %

(3.0) %

(1.5) %

(1.5) %

Core sales growth (decline) (non-GAAP)

2.0 %

4.5 %

3.0 %

(1.0) %

Impact of respiratory testing

2.0 %

5.0 %

Core sales growth excluding respiratory
testing (non-GAAP)

4.0 %

4.0 %

Note: Beginning with the Company's Quarterly Report on Form 10-Q for the second quarter of 2026, in addition to disclosing core sales growth, the Company is disclosing a new non-GAAP measure, titled "Core sales growth excluding respiratory testing." This new measure adjusts core sales to exclude revenues related to the sale of respiratory testing products in the Company's molecular diagnostics business in the Diagnostics segment. Demand for respiratory testing depends significantly on the severity levels of influenza and influenza-like illness in a given period, and these severity levels are not under management's control. As a result, presenting core sales on a basis that combines respiratory testing revenue with other Diagnostics business revenues can obscure underlying growth trends within the Diagnostics businesses.  The Company believes that presenting this additional measure will complement core sales, enhance investors' understanding of the historical and anticipated performance of the Diagnostics businesses and Danaher as a whole, including with respect to underlying growth trends, and facilitate comparisons of period-to-period performance. In addition, beginning with the Company's Quarterly Report on Form 10-Q for the third quarter of 2026, the Company intends to exclude from the core sales measures the impact, if any, of tariff refunds (related to tariff payments made in prior periods) that are returned, or expected to be returned, to customers. The Company believes this adjustment will help investors better understand underlying growth trends in the Company's business that otherwise may be obscured by the above-noted tariff-related impacts.

Non-GAAP Forward-Looking Information

% Change Three-
Month Period Ending
September 25, 2026
vs. Comparable 2025
Period

% Change Three-
Month Period Ending
December 31, 2026
vs. Comparable 2025
Period

% Change Year
Ending December 31,
2026 vs. Comparable
2025 Period

Core sales growth (non-GAAP)

Biotechnology

+Mid-single digit

+Mid-single digit

Life Sciences

+3.0% - +4.0%

+3.0% - +4.0%

Diagnostics

Flat

+Up slightly

Total Company

+2.0% - +3.0%

+Mid-single digit

+3.0% - +4.0%

Impact of respiratory testing

+2.5 %

Flat

+Low-single digit

Core sales growth excluding respiratory testing (non-GAAP)     

~+5.0%

+Mid-single digit

+Mid-single digit

Three-Month Period
Ending

September 25, 2026

Year Ending

December 31, 2026

Adjusted operating profit margin (non-GAAP)

 ~26.5  %

Adjusted diluted net earnings per common share (non-GAAP)

$8.45 - $8.60

Other Forward-Looking Information

Three-Month Period
Ending

September 25, 2026

Year Ending

December 31, 2026

Impact of currency exchange rates on sales H

~(1.0)%

~+0.5%

Amortization of acquisition-related intangible assets ($ in millions)     

~$(500)

~$(1,900)

Corporate expense I ($ in millions)

~$(90)

~$(360)

Interest expense, net J ($ in millions)

~$(115)

~$(310)

Effective tax rate

 ~17.0  %

 ~17.0  %

Average adjusted diluted shares (in millions)

~707

~709

H 

Impact of currency exchange rates on sales for the second quarter and full year 2026 assumes the currency exchange rates in effect as of June 26, 2026.

I 

Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management's evaluation of reportable segment operating performance.

J  

Interest expense, net is defined as interest expense net of interest income. This line item is an assumption rather than a forecast. The estimated interest expense, net is calculated assuming the currency exchange rates in effect as of June 26, 2026 are to prevail throughout the remainder of the period indicated and no change in the amount of commercial paper outstanding.

Pending SLMP LLC "StatLab" Acquisition

Earlier this month, Leica Biosystems, our anatomic pathology business, announced their intention to acquire StatLab, a leading manufacturer of products across the core histology workflow, from specimen collection through slide staining. The business has >85% recurring revenue and is complementary to Leica Biosystems' existing oncology instrument portfolio.

Below is some information on StatLab:

StatLab generated ~$250M in revenue for the full year 2025 The Company expects StatLab to have +high-single digit core sales growth over the long term The Company expects StatLab to be accretive to Adjusted diluted net earnings per common share (non-GAAP) in the 1st full year of ownership The Company expects to close this acquisition by the end of 2026, subject to customary closing conditions and regulatory approvals Historical Sales (Decline) Growth, Core Sales Growth and Core Sales Growth Excluding Respiratory Testing

% Change Three-Month Period Ended vs. Comparable 2024 Period

% Change Year
Ended
December 31,
2025 vs.
Comparable
2024 Period

% Change
Three-Month
Period Ended
March 27, 2026
vs. Comparable
2025 Period

March 28, 2025

June 27, 2025

September 26,
2025

December 31,
2025

Total sales (decline) growth
(GAAP)

(1.0) %

3.5 %

4.5 %

4.5 %

3.0 %

3.5 %

Impact of:

Acquisitions/divestitures

(0.5) %

— %

— %

0.5 %

— %

— %

Currency exchange rates

1.5 %

(2.0) %

(1.5) %

(2.5) %

(1.0) %

(3.0) %

Core sales growth (non-GAAP)

— %

1.5 %

3.0 %

2.5 %

2.0 %

0.5 %

Impact of respiratory testing

1.0 %

0.5 %

(0.5) %

1.5 %

0.5 %

2.5 %

Core sales growth excluding
respiratory testing (non-GAAP)     

1.0 %

2.0 %

2.5 %

4.0 %

2.5 %

3.0 %

Note: For the impact of respiratory testing, a positive amount represents a year-over-year headwind to core sales growth, and a negative amount represents a year-over-year tailwind to core sales growth.

Historical and Forward-Looking Respiratory Testing Sales

($ in millions)

 Three-Month Period Ended

Year
Ended
December
31, 2025 K

Three-Month Period
Ended

Three-Month Period
Ending

Year
Ending
December
31, 2026 K

March 28,
2025

June 27,
2025

September
26, 2025

December
31, 2025

March 27,
2026

June 26,
2026

September
25, 2026

December
31, 2026

Respiratory     
testing
sales L

~$650

~$300

~$500

~$500

~$1,900

~$500

~$250

~$325

~$500

~$1,600

K

Respiratory testing sales amounts for the relevant three-month periods may not add to the year-to-date period amount due to rounding.

L

Actual respiratory testing sales are rounded to the nearest $50 million.

Cash Flow and Free Cash Flow

($ in millions)

Three-Month Period Ended

Year-over-
Year Change

Six-Month Period Ended

Year-over-
Year Change

June 26, 2026

June 27, 2025

June 26, 2026

June 27, 2025

Total Cash Flow:

Net cash provided by
operating activities
(GAAP)

$            1,534

$           1,338

$           2,856

$           2,637

Total cash used in
investing activities
(GAAP)

$         (10,147)

$             (258)

$        (10,396)

$            (500)

Total cash provided by
(used in) financing
activities (GAAP)

$            7,273

$             (247)

$           7,319

$         (1,502)

Free Cash Flow:

Net cash provided by
operating activities
(GAAP)

$            1,534

$           1,338

 ~ 14.5 %

$           2,856

$           2,637

 ~ 8.5   %

Less: payments for
additions to property, plant     
& equipment (capital
expenditures) (GAAP)     

(269)

(248)

(506)

(493)

Plus: proceeds from sales
of property, plant &
equipment (capital
disposals) (GAAP)

—

4

—

10

Free cash flow (non-
GAAP)

$            1,265

$           1,094

 ~ 15.5 %

$           2,350

$           2,154

 ~ 9.0   %

Operating Cash Flow to
Net Earnings
Conversion Ratio:

Net cash provided by
operating activities
(GAAP)

$            1,534

$           1,338

$           2,856

$           2,637

Net earnings (GAAP)

870

555

1,899

1,509

Operating cash flow to net
earnings conversion ratio
(GAAP)

1.76

2.41

1.50

1.75

Free Cash Flow to Net
Earnings Conversion
Ratio:

Free cash flow from
above (non-GAAP)

$            1,265

$           1,094

$           2,350

$           2,154

Net earnings (GAAP)

870

555

1,899

1,509

Free cash flow to net
earnings conversion ratio
(non-GAAP)

1.45

1.97

1.24

1.43

We define free cash flow as operating cash flows, less payments for additions to property, plant and equipment ("capital expenditures") plus the proceeds from sales of plant, property and equipment ("capital disposals"). 

Statement Regarding Non-GAAP Measures

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors:

with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior and future periods and to our peers; with respect to the non-GAAP measures related to core sales, identify underlying growth trends in our business and compare our sales performance with prior and future periods and to our peers; and with respect to free cash flow (the "FCF Measure"), understand Danaher's ability to generate cash without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities (although a limitation of free cash flow is that it does not take into account the Company's debt service requirements and other non-discretionary expenditures, and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures). Management uses the non-GAAP measures referenced above to measure the Company's operating and financial performance, and uses core sales and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Common Share, Adjusted Operating Profit and the FCF Measure in the Company's executive compensation program.

The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:

With respect to the profitability-related non-GAAP measures: Amortization of Intangible Assets: We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Restructuring Charges: We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of our business and we believe are not indicative of Danaher's ongoing operating costs in a given period, we exclude these costs to facilitate a more consistent comparison of operating results over time. Other Adjustments: With respect to the other items excluded from the profitability-related non-GAAP measures, we exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-term performance difficult.  With respect to core sales, (1) we exclude the impact of currency translation because it is not under management's control, is subject to volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business trends and make comparisons of long-term performance difficult. Please see "Sales Growth by Segment, Core Sales Growth (Decline) by Segment and Core Sales Growth Excluding Respiratory Testing" above for an explanation on why we exclude respiratory testing revenues from the non-GAAP measure "Core sales excluding respiratory testing". In addition, beginning with the Company's Quarterly Report on Form 10-Q in the third quarter of 2026, the Company intends to exclude from core sales the impact of tariff refunds related to prior period tariffs that are returned, or expected to be returned, if any, to customers as the Company believes these amounts may obscure underlying business trends.  With respect to the FCF Measure, we deduct payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate the amount of operating cash flow for the period that remains after accounting for the Company's capital expenditure requirements. SOURCE Danaher Corporation

Advanced compute power, built on NVIDIA infrastructure, enables real-time decision support during the procedure

FDA-cleared Instrument Exit Point (IEP), the first real-time AI application for robotic procedures from Medtronic, advances a precise, predictable, and personalized future for surgery

, /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, is presenting an early look at its next-generation compute platform for the operating room. Touch Surgery™ Aide — an AI-native surgical computing platform that powers the Touch Surgery™ ecosystem — enables real-time artificial intelligence during procedures. Touch Surgery™ Aide will be shared at the Society of Robotic Surgery (SRS) 2026 Annual Meeting in Florida, July 23-26.

Touch Surgery(TM) Aide and the Touch Surgery(TM) ecosystem

Hugo(TM) Robotic Assisted Surgery system console and Touch Surgery(TM) ecosystem with the next-generation compute platform Touch Surgery(TM) Aide Built on years of experience, the Touch Surgery™ ecosystem brings insight to surgery, in more than 1,500 operating rooms worldwide. It connects the entire surgical journey: bridging pre-operative planning and training, intra-operative tele-mentoring and tele-proctoring, and AI-powered post-operative insight, simplifying workflows and extending access beyond individual ORs.

Touch Surgery™ Aide expands the Touch Surgery™ ecosystem with next-generation computing capabilities, enabling multimodal AI-driven support during surgery. This provides surgeons with access to actionable insights during procedures, supports case review, and helps inform continuous improvement in clinical decision-making.

"Real-time AI marks a new frontier for healthcare — it is a fundamental evolution in how surgery is supported, moving from technology that assists the surgeon's hand to technology that helps teams work smarter, move faster, and deliver greater impact in the moment," said Jim Peichel, Chief Technology Officer at Medtronic.

Touch Surgery™ Aide incorporates NVIDIA's accelerated computing infrastructure, leveraging the company's Holoscan, CUDA, and TensorRT to deliver AI-powered insights in the moment, supporting surgical decision-making when it matters most. Touch Surgery™ Aide combines computer vision, multimodal AI, and accelerated inference to process surgical video and procedural context in real time. This enables multiple AI applications to run simultaneously during a live procedure, processing and acting on surgical data in the moment. It brings intelligent, increasingly automated support in the OR, and is designed to continuously learn and evolve. 

Medtronic's first real-time AI application for robotic surgery
Instrument Exit Point (IEP) is an AI application that runs on Touch Surgery™ Aide, for use with the Hugo™ robotic-assisted surgery (RAS) system. It received U.S. Food and Drug Administration (FDA) clearance.

Using computer vision, IEP provides a visual notification when select instruments move beyond the visible field of view during a robotic procedure. As the first real-time AI application to run on Touch Surgery™ Aide, IEP represents an early step in bringing AI-enabled support into robotic surgery, with the platform designed to support expansion into laparoscopic surgery over time.

Medtronic continues to progress the capabilities of the Hugo™ robotic-assisted surgery (RAS) system. In December 2025, the Hugo™ RAS system received FDA clearance for use in urologic surgical procedures, bringing a versatile robotic-assisted platform to U.S. surgeons and health systems. In June 2026, Medtronic announced 510(k) submissions to expand the use of the Hugo™ RAS system into general and gynecologic specialties in the U.S. The Hugo™ RAS system continues to have a growing global impact and has been used in tens of thousands of procedures across more than 35 countries in six continents. 

Transforming the future of surgery
This is an early step in a broader effort to bring AI into more of what happens in the operating room. Over time, Medtronic expects the platform to support a growing range of real-time AI applications, connect with other Medtronic technologies in the OR, and turn the data from every case into insight for surgical teams and the hospitals they work in.

"Surgery is on the cusp of a generational shift, powered by AI and advanced compute," said George Murgatroyd, General Manager & Vice President, Digital Technologies within the Surgical business at Medtronic. "The Touch Surgery™ ecosystem, powered by Touch Surgery™ Aide, establishes a platform for a new generation of embedded connectivity, seamlessly integrating advanced capabilities into surgical workflows and reinforcing Medtronic's commitment to delivering the best possible care, for every patient, anywhere."

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Gary Jeanfaivre      

Ingrid Goldberg

Public Relations

Investor Relations

+1-203-556-0777

+1-763-505-2696

SOURCE Medtronic plc

Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) said the exploration timetable for its offshore Uruguay interests has been extended by a year, while an Argentine offshore licensing opportunity moved towards a formal international tender.

Uruguay’s state-owned energy company and regulator ANCAP agreed to suspend the initial exploration period for the AREA OFF-1 block, pushing its expiry date to 23 August 2027. Operator Chevron requested the extension after delays in obtaining environmental approval for a planned 3D seismic programme.

The first seismic acquisition season was completed before the end of April, with a second scheduled to begin in the fourth quarter of 2026. Sintana said the full dataset must be acquired, processed and interpreted before an optimal exploration drilling decision can be made.

Separately, Argentina has instructed its National Secretariat of Energy to call an international public tender for the CAN-200 area in the North Argentine Basin. The process follows a February 2025 expression of interest from Sintana group company Challenger Energy and is a necessary step before a potential exploration permit can be awarded.

The S&P/ASX Small Ordinaries Index gained 8.80 points, or 0.27%, to close at 3,315.00 yesterday, providing some relief after a weaker trading week.

Despite the positive session, the index remained 37.80 points, or 1.13%, lower over the past five days as investors continued to navigate volatile commodity markets and broader economic uncertainty.

Against this mixed market backdrop, several ASX-listed explorers and developers reported operational milestones, drilling results and project advancements across gold, copper, tungsten and nickel assets.

Alkane generates $174 million quarterly operating cash flow Alkane Resources Ltd (ASX:ALK, OTC:ALKEF) produced 42,491 gold-equivalent ounces during the June quarter at an all-in sustaining cost of A$3,011 per ounce.

Full-year production reached 168,337 gold-equivalent ounces at an AISC of A$2,925 per ounce, placing the company in the upper half of its FY2026 guidance range.

The company generated site operating cash flow of A$174 million during the quarter and has forecast FY2027 production of between 163,000 and 177,000 gold-equivalent ounces at an AISC of A$2,900 to A$3,200 per ounce.

Exploration at the Northern Molong Porphyry Project in New South Wales also continued to identify gold-copper mineralisation between the Boda and Kaiser deposits.

Results included 23.5 metres at 0.17 g/t gold and 0.14% copper, along with 42.1 metres at 0.16 g/t gold and 0.14% copper.

A mobile magnetotellurics survey has also defined new target areas across the project for further assessment.

Lightning advances Warby tungsten targets Lightning Minerals Ltd (ASX:L1M, FRA:YZ1) has completed the second phase of exploration at its wholly owned Warby Tungsten Project in North Queensland, moving the project closer to drill target selection.

The program included detailed geological mapping, soil geochemistry, stream sediment concentrate sampling and targeted rock-chip sampling across priority targets identified during the initial reconnaissance campaign.

Lightning said the work was designed to improve its understanding of the scale, continuity and geological controls of the Warby tungsten system.

Results from the program will be used to refine priority areas and guide the company’s next stage of exploration.

Hanrine earns 51% interest in Titan’s Linderos project Titan Minerals Ltd (ASX:TTM, OTC:TTTNF) said Hancock Prospecting subsidiary Hanrine Ecuadorian Exploration and Mining had completed the third milestone under the joint venture and earn-in agreement covering the Linderos Copper Project in Ecuador.

Hanrine has made a US$2 million cash payment, completed 10,000 metres of diamond drilling and spent an aggregate US$20 million on the project.

Completion of the expenditure milestone takes Hanrine’s interest in Linderos to 51%.

Under the agreement, Hanrine had up to seven years to reach the milestone but completed the required work in less than two years.

Hanrine has been fully funding and managing a two-phase, 25,000-metre diamond drilling program at Linderos since the agreement was signed in September 2024.

Saturn secures key Apollo Hill mining lease Saturn Metals Ltd (ASX:STN) has been granted Mining Lease M31/496, marking another important step toward developing the 2.83-million-ounce Apollo Hill Gold Project in Western Australia.

The 11,700-hectare lease surrounds the project’s existing mining leases and incorporates recent resource growth, Saturn’s maiden 1.59-million-ounce ore reserve and its 1.77-million-ounce pre-feasibility production target.

The lease also provides space for potential future resource growth, mine expansion and supporting infrastructure, including bore fields and road corridors.

It follows the execution of the Apollo Hill Native Title Mining and Project Agreement in June 2026.

Saturn is advancing a definitive feasibility study for Apollo Hill, which is scheduled for completion later this year.

Western Mines intersects broad nickel sulphides Western Mines Group Ltd (ASX:WMG) has reported broad zones of nickel sulphide mineralisation from the latest reverse circulation drilling at the Mulga Tank Project in Western Australia’s Eastern Goldfields.

Hole MTRC073 returned a cumulative 173 metres at 0.31% nickel, including 22 metres at 0.44% nickel from 182 metres.

This broader interval contained 3 metres at 1.18% nickel from 189 metres, including 1 metre at 2.25% nickel.

Hole MTRC078 intersected a cumulative 182 metres at 0.30% nickel, including 4 metres at 0.85% nickel from 293 metres and 1 metre at 2.26% nickel from 295 metres.

Western Mines said all six holes for which results were received contained broad nickel sulphide mineralisation, with several intervals returning higher-grade nickel, cobalt and copper values.

Alkane Resources Ltd (ASX:ALK, OTC:ALKEF) has delivered annual production in the upper half of guidance, generated record cash flow and proposed its first dividend following a strong finish to the 2026 financial year.

The gold and antimony producer generated 42,491 gold equivalent ounces in the June quarter at an all-in sustaining cost (AISC) of A$3,011 per ounce, taking full-year production to 168,337 gold equivalent ounces at an AISC of A$2,925 per ounce.

Quarterly mine operating cash flow reached A$174 million, contributing to a post-tax free cash build of A$104 million. Alkane ended June with A$432 million in cash and A$454 million in combined cash, bullion and listed investments.

Reflecting the strengthened balance sheet, the board has proposed a maiden fully franked dividend of 2 cents per share, subject to completion of the audit, statutory dividend tests and final board approval.

Strong sales and operating cash flow Alkane sold 47,411 gold equivalent ounces during the quarter, generating A$257 million in revenue at an average realised gold price of A$5,442 per ounce and an average realised antimony price of A$24,276 per tonne.

Production comprised 40,949 ounces of gold and 456 tonnes of antimony. Output was below the March quarter due primarily to planned grade variations across the company’s three operating mines.

Managing director and CEO Nic Earner said the result demonstrated the strength of Alkane’s expanded operating portfolio.

“Our site operating cash flow was $174 million for the quarter, resulting in a balance sheet with $454 million in cash, bullion and listed investments at quarter end,” Earner said.

“Reflecting this strong financial position and our confidence in the business, the Board has proposed Alkane’s first ever dividend of 2 cents per share, fully franked — a significant milestone for the Company and a tangible return to the shareholders who have supported our growth.”

Three-mine portfolio delivers Tomingley Gold Operations in New South Wales produced 20,896 ounces during the quarter and generated A$76 million in operating cash flow.

The mine achieved record annual gold production, underground ore tonnes and mill throughput during FY26, while work continued on the Newell Highway diversion required to support the operation’s expansion.

At the Costerfield gold-antimony operation in Victoria, Alkane produced 11,659 gold equivalent ounces and generated A$50 million in operating cash flow.

Exploration drilling at Brunswick South extended the high-grade gold-antimony trend, with notable results including 2.17 metres at 50.1 g/t gold and 26.2% antimony, and 0.65 metres at 109.9 g/t gold and 3.1% antimony.

Björkdal in Sweden produced 9,935 ounces of gold and contributed A$49 million in operating cash flow. Exploration continued along the northern and eastern extensions of the mine and at the nearby Storheden deposit.

Boda-Kaiser exploration advances At the Northern Molong Porphyry Project in New South Wales, drilling between the Boda and Kaiser deposits intersected further gold-copper mineralisation within an intrusive-hydrothermal breccia system.

Results included 23.5 metres at 0.17 g/t gold and 0.14% copper and 42.1 metres at 0.16 g/t gold and 0.14% copper.

A mobile magnetotelluric survey also identified six high-priority porphyry targets north of Boda-Kaiser, including targets at Driell Creek, Murga, Gollan North, One Tree and Old Station. Ground validation has begun ahead of further drill targeting.

FY27 guidance and next steps Alkane has forecast FY27 production of between 163,000 and 177,000 gold equivalent ounces at an AISC of A$2,900 to A$3,200 per ounce.

The company expects to spend A$55 million to A$65 million on exploration and A$160 million to A$190 million on growth capital.

Key programs include the Newell Highway diversion at Tomingley, development of Brunswick South at Costerfield, initial development at Storheden, expansion of Björkdal’s tailings facilities and equipment replacement across the group.

About Alkane Resources Alkane Resources is an Australian-based gold and antimony producer operating the Tomingley gold mine in New South Wales, the Costerfield gold-antimony mine in Victoria and the Björkdal gold mine in Sweden.

The company also owns the large Boda-Kaiser gold-copper porphyry project within the Northern Molong Porphyry Project in Central West New South Wales.

Ground testing of flight-standard engine and propeller for RTX Hybrid-Electric Flight Demonstrator begins in Quebec

, /PRNewswire/ -- Farnborough International Airshow – Pratt & Whitney Canada today announced a new phase in the RTX Hybrid-Electric Flight Demonstrator project, with ground testing of the flight-standard propulsion system and propeller in Longueuil, Quebec. Following completion of the ground test, the hybrid-electric propulsion system will be installed on the De Havilland Canada Dash 8-100 experimental aircraft, with the first flight expected in 2027. Pratt & Whitney is an RTX (NYSE: RTX) business.

"Assembling the final, flight-standard propulsion system brings us one step closer to proving hybrid-electric technology in flight," said Jean Thomassin, executive director, New Products and Services Introduction, Pratt & Whitney Canada. "We are advancing thermal engine and hybrid-electric technologies which could enhance fuel efficiency and performance for a wide range of future aircraft applications."

The hybrid-electric propulsion system combines an advanced Pratt & Whitney Canada thermal engine with a 1-megawatt electric motor and motor controller developed by RTX's Collins Aerospace, along with a battery system supplied by H55 S.A., a Swiss developer of certifiable aviation energy storage systems.

With the electric motor providing additional power during demanding flight phases such as takeoff and climb, the hybrid-electric architecture enables the propulsion system to operate more efficiently throughout the flight mission. The project aims to demonstrate up to 30% improved fuel efficiency for a typical 250-nautical-mile regional turboprop mission.

The RTX Hybrid-Electric Flight Demonstrator project has accelerated collaboration between leading aerospace industry companies and research institutions within Canada and abroad, including De Havilland Aircraft of Canada, GKN Aerospace, AeroTEC, Ricardo, the National Research Council of Canada and the Innovative Vehicle Institute.

The project is supported by the governments of Canada and Quebec. Additionally, the project's propulsion system verification phase is supported by Strix, the organization managing Canada's Initiative for Sustainable Aviation Technology (INSAT), with funding from the Government of Canada, as part of its fifth wave of innovative research projects.

Learn more about how RTX is developing transformative technologies in Canada here.

About Pratt & Whitney
Pratt & Whitney, an RTX business, is a world leader in the design, manufacture and service of aircraft engines and auxiliary power units for military, commercial and civil aviation customers. Since 1925, our engineers have pioneered the development of revolutionary aircraft propulsion technologies, and today we support more than 90,000 in-service engines through our global network of maintenance, repair and overhaul facilities.

About RTX
With more than 180,000 global employees, we push the limits of technology and science to redefine how we connect and protect our world. With industry-leading capabilities, we advance aviation, engineer integrated defense systems for operational success, and develop next-generation technology solutions and manufacturing to help global customers address their most critical challenges. The company, with 2025 sales of more than $88 billion, is headquartered in Arlington, Virginia.

For questions or to schedule an interview, please contact [email protected].

SOURCE RTX

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden lowered its position in shares of Intuit Inc. (NASDAQ:INTU – Free Report) by 23.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 50,280 shares of the software maker’s stock after selling 15,280 shares during the period. Andra AP fonden’s holdings in Intuit were worth $21,740,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in INTU. Joseph Group Capital Management bought a new stake in shares of Intuit during the fourth quarter valued at approximately $25,000. Intesa Sanpaolo Wealth Management purchased a new position in shares of Intuit in the fourth quarter worth $25,000. HHM Wealth Advisors LLC raised its stake in shares of Intuit by 75.0% in the first quarter. HHM Wealth Advisors LLC now owns 70 shares of the software maker’s stock worth $30,000 after purchasing an additional 30 shares during the last quarter. Whipplewood Advisors LLC bought a new position in shares of Intuit during the first quarter valued at $30,000. Finally, CrossGen Wealth LLC bought a new position in shares of Intuit during the first quarter valued at $32,000. Institutional investors own 83.66% of the company’s stock.

Analyst Ratings Changes Several equities research analysts recently commented on the company. Argus reduced their price objective on Intuit from $580.00 to $480.00 and set a “buy” rating for the company in a report on Friday, May 22nd. Daiwa Securities Group dropped their price target on shares of Intuit from $640.00 to $500.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Bank of America assumed coverage on shares of Intuit in a research note on Wednesday, May 27th. They issued a “buy” rating and a $400.00 price target for the company. Wall Street Zen cut shares of Intuit from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Finally, Stifel Nicolaus restated a “hold” rating and set a $275.00 price objective (down from $375.00) on shares of Intuit in a research report on Wednesday, June 17th. Twenty-two analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $486.42.

View Our Latest Research Report on INTU

Insider Activity In other news, Director Vasant M. Prabhu bought 1,250 shares of Intuit stock in a transaction that occurred on Friday, May 22nd. The stock was bought at an average cost of $309.45 per share, with a total value of $386,812.50. Following the acquisition, the director owned 1,250 shares of the company’s stock, valued at $386,812.50. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard L. Dalzell sold 338 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $279.86, for a total transaction of $94,592.68. Following the sale, the director owned 12,326 shares in the company, valued at approximately $3,449,554.36. The trade was a 2.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,239 shares of company stock worth $348,354 in the last ninety days. Corporate insiders own 2.49% of the company’s stock.

More Intuit News Here are the key news stories impacting Intuit this week:

Negative Sentiment: Several law firms issued fresh reminders about the pending class action and September 8 lead plaintiff deadline, highlighting ongoing litigation risk for Intuit investors. Article Title Negative Sentiment: New notices from Faruqi & Faruqi, Glancy Prongay Wolke & Rotter, Levi & Korsinsky, Robbins LLP, and BFA Law reinforce that a securities fraud lawsuit has already been filed against Intuit. Article Title Negative Sentiment: One report says Intuit was accused of misrepresentations about pricing issues, adding to the legal overhang that may pressure the stock. Article Title Neutral Sentiment: Analyst commentary noted TurboTax Live is performing well, while Intuit also plans to revamp DIY tax products with simpler offerings, better pricing, and expanded financial services to regain cost-conscious filers. Article Title Neutral Sentiment: Susquehanna cut its price target on Intuit to $427 from $550 but kept a positive rating, which signals some caution but still implies upside from current levels. Positive Sentiment: Several articles framed the recent decline in Intuit (INTU) as potentially overdone, suggesting some investors see the pullback as a buying opportunity. Article Title Intuit Price Performance NASDAQ INTU opened at $293.82 on Tuesday. Intuit Inc. has a 52 week low of $252.84 and a 52 week high of $813.70. The firm has a market capitalization of $80.37 billion, a P/E ratio of 17.80, a PEG ratio of 1.07 and a beta of 1.00. The company has a quick ratio of 1.45, a current ratio of 1.45 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average price of $301.21 and a 200-day moving average price of $402.03.

Intuit (NASDAQ:INTU – Get Free Report) last issued its quarterly earnings data on Wednesday, May 20th. The software maker reported $12.80 earnings per share for the quarter, topping the consensus estimate of $12.57 by $0.23. The firm had revenue of $8.56 billion for the quarter, compared to analysts’ expectations of $8.54 billion. Intuit had a net margin of 21.91% and a return on equity of 25.18%. The business’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $11.65 EPS. Intuit has set its Q4 2026 guidance at 3.560-3.620 EPS and its FY 2026 guidance at 23.800-23.850 EPS. Equities research analysts anticipate that Intuit Inc. will post 18.18 earnings per share for the current year.

Intuit Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Thursday, July 9th were paid a $1.20 dividend. The ex-dividend date of this dividend was Thursday, July 9th. This represents a $4.80 annualized dividend and a dividend yield of 1.6%. Intuit’s dividend payout ratio (DPR) is 29.07%.

Intuit Company Profile (Free Report)

Intuit Inc (NASDAQ: INTU) is a financial software company headquartered in Mountain View, California, that develops and sells cloud-based financial management and compliance products for individuals, small businesses, self-employed workers and accounting professionals. Founded in 1983 by Scott Cook and Tom Proulx, the company has grown from desktop tax and accounting software into a diversified provider of online financial tools. As of my latest update, Sasan Goodarzi serves as Chief Executive Officer.

Intuit’s product portfolio includes QuickBooks, its flagship accounting and business-management platform that offers bookkeeping, payroll, payments and invoicing capabilities; TurboTax, a tax-preparation and filing service aimed at individual taxpayers; and Mint, a consumer personal-finance and budgeting app.

Further Reading Five stocks we like better than Intuit The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding INTU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuit Inc. (NASDAQ:INTU – Free Report).

Receive News & Ratings for Intuit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuit and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Grows Stake in The Charles Schwab Corporation $SCHW

NEXT HEADLINE »Andra AP fonden Has $28.51 Million Stake in Morgan Stanley $MS

SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Intuit Inc. (NASDAQ: INTU) securities between August 22, 2025 and May 20, 2026, both dates inclusive (the “Class Period”), have until September 8, 2026 to seek appointment as lead plaintiff of the Intuit class action lawsuit. Captioned Baldwin v. Intuit Inc., No. 26-cv-07086 (N.D. Cal.), the Intuit class action lawsuit charges Intuit as well as certain of Intuit’s top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Intuit class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-intuit-inc-class-action-lawsuit-intu.html

You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Intuit provides financial management, payments and capital, compliance, and marketing products and services.

The Intuit class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) they had overstated Intuit’s competitive advantages and growth, as well as the overall strength and sustainability of its business model and operations; (ii) in reality, Intuit was losing significant business in its tax-related business, particularly in its Turbo Tax business, as a result of, among other things, increasing competitive and pricing pressures; and (iii) accordingly, Intuit’s previously issued 2026 TurboTax revenue growth guidance was unreliable and/or unrealistic.

On May 20, 2026, during pre-market hours, Reuters published an article entitled “Intuit to cut 17% of global jobs to streamline operations, memo shows,” allegedly reporting that Intuit “is laying off about 17% of its workforce, or about 3,000 employees worldwide.” On this news, the price of Intuit stock dropped nearly 4%, according to the complaint.

Later that day, during post-market hours, Intuit issued a press release announcing its fiscal third quarter 2026 results, allegedly reporting weak Q3 2026 tax season revenue, including that TurboTax revenue grew by only 7% year-over-year versus consensus estimates of at least 8% revenue growth. The Intuit class action lawsuit further alleges that on an accompanying conference call that day, Sasan K. Goodarzi, Intuit’s Chairman and CEO, disclosed that TurboTax online paying units were expected to grow by only 2% as total Internal Revenue Service filers were expected to decline by approximately 30 basis points, representing the “most significant industry-wide contraction since the post-COVID tax season.” On this news, the price of Intuit stock dropped over 20%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Intuit securities during the Class Period to seek appointment as lead plaintiff in the Intuit class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Intuit class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Intuit class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Intuit class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        Ken Dolitsky
        Michael Albert
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800/851-7783
        [email protected]

July 21, 2026 07:00 ET  | Source: Scotts Miracle-Gro Company (The)

GroForward 2030 focuses on products, practices and people

Initiative outlined in 2026 Corporate Responsibility Report

MARYSVILLE, Ohio, July 21, 2026 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the leading marketer of branded consumer lawn and garden products in North America, today announced the release of its 2026 Corporate Responsibility Report.

The report, available on the ScottsMiracle-Gro website, memorializes the Company’s progress in 2025 toward its corporate responsibility commitments and demonstrates a shift in its approach to corporate responsibility through 2030, branded as GroForward 2030 and grounded in delivering responsibly produced solutions backed by science and built for real life. GroForward 2030 aims to best serve the Company’s stakeholders while embodying its purpose to GroMoreGood, everywhere.

“GroForward 2030 builds on our history of success in sustainability to create many more opportunities for positive impacts to the benefit of our Company and all those with whom we do business,” said Nate Baxter, president and CEO. “Just as importantly, our reinvigorated approach to corporate responsibility is a reflection of input from our stakeholders and aligns with our multi-year SMG 2.0 growth strategy.”

Baxter noted that the consumer and retail environment are changing, and the Company is adapting through SMG 2.0, whose key elements include:

Innovation to optimize the portfolio, including more products centered on naturals, organics and indoor and outdoor growing.Channel expansion, primarily ecommerce but also in expanded retailer partnerships and professional do-it-for-me yard care.Category growth by engaging emerging consumers and broader demographic groups.Operational efficiencies and savings to ensure the best-in-class supply chain. GroForward 2030 builds on SMG 2.0 with goals centered on the core principles of Products you can count on, Practices you can be proud of and People you grow with.

GroForward 2030 Goals

Products You Can Count On

Designing for Sustainability: 100% of new products introduced will align with at least one defined sustainability criterion mapped directly to the UN Sustainable Development Goals (SDGs 3, 12 and 15).Consumer Experience: Increase the percentage of the ScottsMiracle-Gro product catalog with an average consumer star rating of 4.0 or higher by 25% from the fiscal 2025 baseline. Practices You Can Be Proud Of

Climate and Energy Efficiency: Reduce total absolute Scope 1 and Scope 2 greenhouse gas emissions by 20% by fiscal 2030 from a fiscal 2024 baseline.Environmental Stewardship: Drive a 10% reduction in purchased water intensity across all operated facilities against a fiscal 2024 baseline to build operational resource efficiency. People You Grow With

Supporting Communities: Achieve a 50% associate participation rate in the Company’s Give Back to Gro volunteer time off program.Biodiversity Investment: Support the protection, management or restoration of at least 3,000 acres of natural habitat through biodiversity-related grants and partnerships.Community Impact: Invest $10 million to improve communities through strategic partnerships and charitable contributions. Among milestones achieved in 2025 and recognized in the report:

Product Innovation: 50% sales growth of Miracle-Gro Organics, the successful revival of the O.M. Scott & Sons heritage brand with 100% curbside-recyclable packaging and targeted pest-control technology, such as the new Ortho Mosquito Kill & Prevent product.Eco-Efficiency and Sourcing: Manufacturing of growing media within 150 miles of point-of-sale destinations to lower fuel use and source locally, 40% reduction in energy usage for compressed air in the Marysville fertilizer plant and diversion of 344,445 pounds of plastic waste diverted from landfills through the Trex recycling partnership.Associate Well-Being: Launch of Lyra Health mental wellness platform and earning the Human Rights Campaign's Equality 100 Leader title for the fourth consecutive year.Community Impact: The Scotts Miracle-Gro Foundation distributing $1.96 million in grants, and Marysville campus associate gardens donating over 6,700 pounds of fresh produce to local Ohio food banks. About ScottsMiracle-Gro
With approximately $3.3 billion in sales, the Company is the leading marketer of branded consumer lawn and garden products in North America. The Company’s brands are among the most recognized in the industry. The Company’s Scotts®, Miracle-Gro®, Ortho® and Tomcat® brands are market-leading in their categories. For additional information, visit us at www.scottsmiraclegro.com.

For media inquiries:
Tom Matthews
Chief Communications Officer
[email protected]
(937) 844-3864

For investor inquiries:
Brad Chelton
Vice President
Treasury, Tax and Investor Relations
[email protected]
(937) 309-2503

MILWAUKEE--(BUSINESS WIRE)--Rockwell Automation, Inc. (NYSE: ROK) is scheduled to report its third quarter fiscal 2026 results on Tuesday, Aug. 4, before the market opens. The release will be posted on the Rockwell Investor Relations website at www.rockwellautomation.com/en-us/investors.html. A conference call to discuss the quarterly results will be held at 7:30 a.m. CDT on Aug. 4. This call will be audio webcast and accessible on the Rockwell Automation Investor Relations website. Presentatio.

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. increased its holdings in shares of Roblox Corporation (NYSE:RBLX – Free Report) by 17.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,238,160 shares of the company’s stock after purchasing an additional 469,379 shares during the quarter. Roblox makes up approximately 2.6% of Amova Asset Management Americas Inc.’s portfolio, making the stock its 9th biggest position. Amova Asset Management Americas Inc. owned approximately 0.48% of Roblox worth $183,247,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Baird Financial Group Inc. boosted its holdings in shares of Roblox by 1.4% in the 2nd quarter. Baird Financial Group Inc. now owns 7,294 shares of the company’s stock valued at $767,000 after buying an additional 102 shares in the last quarter. Sunbelt Securities Inc. lifted its position in Roblox by 58.7% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the company’s stock valued at $39,000 after acquiring an additional 105 shares during the last quarter. Brown Brothers Harriman & Co. boosted its stake in Roblox by 2.8% in the third quarter. Brown Brothers Harriman & Co. now owns 4,042 shares of the company’s stock valued at $560,000 after acquiring an additional 110 shares in the last quarter. NewEdge Advisors LLC boosted its stake in Roblox by 1.3% in the second quarter. NewEdge Advisors LLC now owns 10,374 shares of the company’s stock valued at $1,091,000 after acquiring an additional 138 shares in the last quarter. Finally, L2 Asset Management LLC grew its holdings in shares of Roblox by 5.9% during the third quarter. L2 Asset Management LLC now owns 2,783 shares of the company’s stock worth $386,000 after purchasing an additional 154 shares during the last quarter. 94.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Roblox In related news, Director Gregory Baszucki sold 16,666 shares of Roblox stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $57.69, for a total value of $961,461.54. Following the sale, the director directly owned 1,277,835 shares in the company, valued at $73,718,301.15. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO David Baszucki sold 50,628 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $45.28, for a total value of $2,292,435.84. Following the transaction, the chief executive officer directly owned 852,214 shares in the company, valued at $38,588,249.92. This represents a 5.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 161,983 shares of company stock valued at $7,580,990. 10.05% of the stock is owned by company insiders.

Roblox Trading Up 3.2% NYSE:RBLX opened at $53.31 on Tuesday. The firm has a market cap of $35.80 billion, a P/E ratio of -33.74 and a beta of 1.41. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 2.45. Roblox Corporation has a 12-month low of $40.15 and a 12-month high of $150.59. The stock’s 50 day simple moving average is $48.72 and its 200-day simple moving average is $58.70.

Roblox (NYSE:RBLX – Get Free Report) last issued its earnings results on Thursday, April 30th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.06. Roblox had a negative net margin of 20.69% and a negative return on equity of 277.69%. The business had revenue of $1.44 billion for the quarter, compared to the consensus estimate of $1.74 billion. During the same quarter in the previous year, the firm earned ($0.32) earnings per share. The business’s quarterly revenue was up 43.4% compared to the same quarter last year. Equities analysts anticipate that Roblox Corporation will post -1.39 EPS for the current year.

Roblox declared that its Board of Directors has initiated a share buyback plan on Tuesday, May 19th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 9.5% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets RBLX has been the subject of several research reports. BTIG Research downgraded Roblox from a “buy” rating to a “neutral” rating in a report on Friday, May 1st. Barclays raised Roblox from an “equal weight” rating to an “outperform” rating in a research report on Monday, June 29th. Wells Fargo & Company boosted their price objective on Roblox from $55.00 to $56.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Oppenheimer started coverage on shares of Roblox in a research report on Friday, May 1st. They set an “outperform” rating on the stock. Finally, Piper Sandler cut shares of Roblox from an “overweight” rating to a “neutral” rating and cut their target price for the company from $100.00 to $50.00 in a report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Roblox has a consensus rating of “Moderate Buy” and a consensus price target of $85.48.

Get Our Latest Stock Report on RBLX

Key Headlines Impacting Roblox Here are the key news stories impacting Roblox this week:

Positive Sentiment: Investors are bidding up Roblox ahead of its July 30 second-quarter earnings release, with traders positioning for a potentially strong update on summer engagement and user growth. Roblox gains as investors look ahead to earnings and recent platform updates Positive Sentiment: Recent product changes, including the rollout of Roblox Kids and Roblox Select accounts, may be improving sentiment by showing the company is tightening safety controls while expanding its age-based offerings. Roblox gains as investors look ahead to earnings and recent platform updates Neutral Sentiment: Analyst commentary remains constructive, with recent coverage describing Roblox as favorably positioned versus Take-Two thanks to user growth, creator incentives, and AI capabilities. Roblox vs. Take-Two: Which Gaming Stock Has the Edge Now? Negative Sentiment: Multiple law firms are advertising securities class-action claims and lead-plaintiff deadlines tied to Roblox’s stock performance during the October 2025 to April 2026 period, which could weigh on sentiment and keep legal risk in focus. RBLX Investors Have Opportunity to Lead Roblox Corporation Securities Fraud Lawsuit with the Schall Law Firm Negative Sentiment: Fresh litigation notices from Rosen Law Firm, Hagens Berman, and Bronstein, Gewirtz & Grossman extend the legal overhang and may remind investors of potential costs and distraction for management. HBSS Investigating Claims Against Roblox (RBLX) In Pending Securities Class Action Roblox Profile (Free Report)

Roblox Corporation operates Roblox, a user-generated online platform that enables people to create, share and monetize immersive 3D experiences and games. The core offering centers on Roblox Studio, a development environment that allows independent creators and studios to design interactive worlds using the company’s building tools and scripting language. Content on the platform spans games, virtual hangouts, branded experiences and live events, all delivered through a persistent social environment.

Roblox’s business model is built around its virtual economy and creator ecosystem.

See Also Five stocks we like better than Roblox The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding RBLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roblox Corporation (NYSE:RBLX – Free Report).

Receive News & Ratings for Roblox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roblox and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Increases Stake in Robinhood Markets, Inc. $HOOD

NEXT HEADLINE »AlTi Global Inc. Invests $527,000 in Western Midstream Partners, LP $WES

Chubb Limited (NYSE:CB) will release its second quarter earnings report after the closing bell on Tuesday, July 21.

Analysts expect the Zurich, Switzerland-based company to report quarterly earnings of $6.73 per share, up from $6.14 per share in the year-ago period. The consensus estimate for Chubb’s quarterly revenue is $13.01 billion. It reported $12.39 billion last year, according to Benzinga Pro.

On May 21, Chubb raised its quarterly dividend from 97 cents to $1.02 per share and announced a $7.5 billion buyback plan.

Chubb shares gained 0.1% to close at $352.53 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Considering buying CB stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Posted by Defense World Staff on Jul 21st, 2026

Amova Asset Management Americas Inc. boosted its holdings in shares of Schrodinger, Inc. (NASDAQ:SDGR – Free Report) by 13.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,190,837 shares of the company’s stock after purchasing an additional 371,167 shares during the period. Amova Asset Management Americas Inc. owned about 4.32% of Schrodinger worth $36,248,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC raised its position in Schrodinger by 722.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,374 shares of the company’s stock valued at $25,000 after acquiring an additional 1,207 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Schrodinger during the 4th quarter worth approximately $26,000. Hantz Financial Services Inc. grew its stake in shares of Schrodinger by 5,025.8% during the 4th quarter. Hantz Financial Services Inc. now owns 1,589 shares of the company’s stock worth $28,000 after purchasing an additional 1,558 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Schrodinger during the 4th quarter valued at approximately $36,000. Finally, State of Wyoming purchased a new position in shares of Schrodinger during the 2nd quarter valued at approximately $39,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Schrodinger Stock Performance Shares of NASDAQ SDGR opened at $15.00 on Tuesday. The firm has a market cap of $1.11 billion, a PE ratio of -10.64 and a beta of 1.62. The firm has a fifty day moving average of $14.93 and a 200 day moving average of $13.94. Schrodinger, Inc. has a one year low of $10.94 and a one year high of $23.75.

Schrodinger (NASDAQ:SDGR – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.25). Schrodinger had a negative net margin of 40.61% and a negative return on equity of 30.85%. The company had revenue of $58.59 million for the quarter, compared to analysts’ expectations of $47.57 million. During the same period in the previous year, the business earned ($0.82) earnings per share. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities analysts predict that Schrodinger, Inc. will post -1.89 EPS for the current fiscal year.

Analyst Ratings Changes A number of analysts recently issued reports on SDGR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Schrodinger in a report on Wednesday, July 15th. KeyCorp decreased their price objective on shares of Schrodinger from $25.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday, April 8th. Morgan Stanley lowered their target price on shares of Schrodinger from $19.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Thursday, May 14th. Finally, Wall Street Zen cut Schrodinger from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Four equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Schrodinger currently has a consensus rating of “Hold” and a consensus target price of $20.25.

View Our Latest Report on Schrodinger

Schrodinger Profile (Free Report)

Schrödinger, Inc is a life sciences and materials discovery company that specializes in the application of physics-based computational platforms to accelerate drug discovery and advanced materials design. Founded in 1990 by Professor Richard A. Friesner, Schrödinger has developed a suite of proprietary software tools—such as Maestro for molecular modeling, Glide for molecular docking and Jaguar for quantum chemistry calculations—that enable scientists to predict molecular behavior with high accuracy.

Further Reading Five stocks we like better than Schrodinger The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding SDGR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Schrodinger, Inc. (NASDAQ:SDGR – Free Report).

Receive News & Ratings for Schrodinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schrodinger and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Acquires 18,322 Shares of Datadog, Inc. $DDOG

NEXT HEADLINE »Amova Asset Management Americas Inc. Sells 801,804 Shares of Recursion Pharmaceuticals, Inc. $RXRX

Posted by Defense World Staff on Jul 21st, 2026

Andra AP fonden raised its stake in shares of The Sherwin-Williams Company (NYSE:SHW – Free Report) by 23.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,380 shares of the specialty chemicals company’s stock after buying an additional 14,360 shares during the quarter. Andra AP fonden’s holdings in Sherwin-Williams were worth $24,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Wilkerson Advisory Group LLC increased its holdings in shares of Sherwin-Williams by 172.4% in the first quarter. Wilkerson Advisory Group LLC now owns 79 shares of the specialty chemicals company’s stock worth $25,000 after purchasing an additional 50 shares during the last quarter. Ares Financial Consulting LLC bought a new position in Sherwin-Williams during the fourth quarter valued at approximately $27,000. Lloyd Advisory Services LLC. purchased a new position in Sherwin-Williams during the 4th quarter valued at approximately $27,000. Whipplewood Advisors LLC bought a new stake in Sherwin-Williams in the 1st quarter worth approximately $28,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Sherwin-Williams during the 4th quarter worth approximately $30,000. Hedge funds and other institutional investors own 77.67% of the company’s stock.

Wall Street Analysts Forecast Growth SHW has been the topic of several research reports. Berenberg Bank set a $380.00 price target on shares of Sherwin-Williams in a research report on Monday, June 8th. Wells Fargo & Company dropped their price objective on shares of Sherwin-Williams from $365.00 to $350.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. Royal Bank Of Canada restated an “outperform” rating and issued a $405.00 target price (up from $391.00) on shares of Sherwin-Williams in a report on Wednesday, July 8th. JPMorgan Chase & Co. lowered their price target on shares of Sherwin-Williams from $385.00 to $365.00 and set an “overweight” rating for the company in a report on Wednesday, April 29th. Finally, Mizuho dropped their price target on Sherwin-Williams from $410.00 to $371.00 and set an “outperform” rating for the company in a research report on Monday, March 23rd. Eight research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Sherwin-Williams has a consensus rating of “Moderate Buy” and a consensus price target of $374.38.

View Our Latest Stock Report on SHW

Sherwin-Williams Price Performance Sherwin-Williams stock opened at $323.98 on Tuesday. The firm has a 50-day moving average price of $319.95 and a 200-day moving average price of $332.52. The firm has a market capitalization of $79.91 billion, a PE ratio of 31.09, a price-to-earnings-growth ratio of 2.86 and a beta of 1.10. The company has a current ratio of 0.86, a quick ratio of 0.53 and a debt-to-equity ratio of 2.10. The Sherwin-Williams Company has a 12-month low of $289.86 and a 12-month high of $379.65.

Sherwin-Williams (NYSE:SHW – Get Free Report) last issued its quarterly earnings results on Tuesday, April 28th. The specialty chemicals company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.27 by $0.08. Sherwin-Williams had a net margin of 10.86% and a return on equity of 64.55%. The company had revenue of $5.67 billion for the quarter, compared to the consensus estimate of $5.56 billion. During the same period in the prior year, the firm posted $2.25 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. Sherwin-Williams has set its FY 2026 guidance at 11.500-11.900 EPS. As a group, equities research analysts forecast that The Sherwin-Williams Company will post 11.78 EPS for the current year.

Sherwin-Williams Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, June 5th. Shareholders of record on Friday, May 22nd were paid a $0.80 dividend. The ex-dividend date was Friday, May 22nd. This represents a $3.20 dividend on an annualized basis and a yield of 1.0%. Sherwin-Williams’s dividend payout ratio (DPR) is presently 30.71%.

About Sherwin-Williams (Free Report)

Sherwin-Williams (NYSE: SHW) is a global manufacturer and distributor of paints, coatings and related products. Founded in 1866 and headquartered in Cleveland, Ohio, the company supplies a broad range of coatings for residential, commercial and industrial applications. Its product offering includes architectural paints and stains, industrial and protective coatings, automotive finishes, and a variety of sundry products such as primers, sealants and specialty treatments used by professionals and consumers.

The company sells through multiple channels, including a large network of company-operated retail paint stores that serve professional contractors and do-it-yourself consumers, as well as through distributors and mass retailers.

Read More Five stocks we like better than Sherwin-Williams The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Sherwin-Williams Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sherwin-Williams and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAndra AP fonden Boosts Stock Position in The Walt Disney Company $DIS

NEXT HEADLINE »Andra AP fonden Grows Stake in McDonald’s Corporation $MCD

Posted by Defense World Staff on Jul 21st, 2026

AlTi Global Inc. trimmed its position in Royalty Pharma PLC (NASDAQ:RPRX – Free Report) by 50.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,073 shares of the biopharmaceutical company’s stock after selling 25,554 shares during the period. AlTi Global Inc.’s holdings in Royalty Pharma were worth $1,203,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. LM Advisors LLC bought a new stake in Royalty Pharma during the fourth quarter worth approximately $26,000. Lloyd Advisory Services LLC. acquired a new stake in shares of Royalty Pharma during the 4th quarter valued at $30,000. Private Trust Co. NA boosted its stake in shares of Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 288 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Royalty Pharma by 173.4% during the 1st quarter. Blue Trust Inc. now owns 689 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 437 shares in the last quarter. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of Royalty Pharma by 66.4% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 446 shares during the last quarter. 54.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades Several equities research analysts have recently commented on RPRX shares. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. UBS Group lifted their price target on Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, April 21st. Weiss Ratings downgraded Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. Morgan Stanley upped their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research note on Friday, April 10th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $56.57.

View Our Latest Stock Analysis on Royalty Pharma

Royalty Pharma Stock Down 1.5% Shares of Royalty Pharma stock opened at $57.29 on Tuesday. The stock has a 50-day moving average price of $55.12 and a 200 day moving average price of $48.72. The company has a market cap of $32.99 billion, a P/E ratio of 38.97, a P/E/G ratio of 10.30 and a beta of 0.43. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a 1 year low of $34.08 and a 1 year high of $59.44.

Royalty Pharma (NASDAQ:RPRX – Get Free Report) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.08. The company had revenue of $630.58 million for the quarter, compared to analysts’ expectations of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. As a group, analysts expect that Royalty Pharma PLC will post 5.18 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.6%. Royalty Pharma’s dividend payout ratio is 63.95%.

Insider Transactions at Royalty Pharma In related news, EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $56.52, for a total transaction of $5,652,000.00. Following the completion of the sale, the executive vice president owned 459,399 shares of the company’s stock, valued at approximately $25,965,231.48. This trade represents a 17.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gregory Norden sold 3,045 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.00, for a total value of $161,385.00. Following the completion of the transaction, the director owned 191,803 shares in the company, valued at $10,165,559. This trade represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 427,800 shares of company stock valued at $23,333,723 in the last three months. 18.84% of the stock is currently owned by insiders.

Royalty Pharma Company Profile (Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

Featured Articles Five stocks we like better than Royalty Pharma The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAmova Asset Management Americas Inc. Sells 4,933 Shares of MercadoLibre, Inc. $MELI

NEXT HEADLINE »Amova Asset Management Americas Inc. Sells 1,092,615 Shares of Roku, Inc. $ROKU